Trial Outcomes & Findings for Real-World Observational Study Of Zavicefta to Characterize Use Patterns (NCT NCT03923426)
NCT ID: NCT03923426
Last Updated: 2024-06-21
Results Overview
The number of participants classified according to reason for discontinuing for prior antibiotic therapy were reported in this outcome measure. One participant could have more than 1 reason of discontinuation for prior antibiotic therapy.
Recruitment status
COMPLETED
Target enrollment
572 participants
Primary outcome timeframe
Up to 90 days prior to index date (from the data evaluated in approximately 40 months of this study)
Results posted on
2024-06-21
Participant Flow
Participants who were hospitalized with gram-negative infection and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study. Participants were recruited across Europe and Latin America and were followed from ceftazidime-avibactam initiation until 60 days post hospital discharge, mortality, withdrawal from the study, or loss-to-follow-up, whichever occurred first.
Data was abstracted from medical records and evaluated over approximately 40 months of this study.
Participant milestones
| Measure |
Ceftazidime-avibactam
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Overall Study
STARTED
|
572
|
|
Overall Study
Full Analysis Set
|
569
|
|
Overall Study
COMPLETED
|
417
|
|
Overall Study
NOT COMPLETED
|
155
|
Reasons for withdrawal
| Measure |
Ceftazidime-avibactam
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Overall Study
Other
|
19
|
|
Overall Study
Lost to Follow-up
|
16
|
|
Overall Study
Death
|
107
|
|
Overall Study
Incomplete response to question
|
13
|
Baseline Characteristics
Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
Baseline characteristics by cohort
| Measure |
Ceftazidime-avibactam
n=569 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Age, Continuous
FAS72+
|
58.3 Years
STANDARD_DEVIATION 18.37 • n=516 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Age, Continuous
FAS72-
|
59.7 Years
STANDARD_DEVIATION 17.99 • n=53 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Sex: Female, Male
FAS72+ · Female
|
164 Participants
n=516 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Sex: Female, Male
FAS72+ · Male
|
352 Participants
n=516 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Sex: Female, Male
FAS72- · Female
|
20 Participants
n=53 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Sex: Female, Male
FAS72- · Male
|
33 Participants
n=53 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Their Employment Status
Full Time
|
78 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Their Employment Status
Part Time
|
5 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Their Employment Status
Unemployed
|
67 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Their Employment Status
Retired
|
159 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Their Employment Status
Not Available
|
207 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Height: FAS72+ Analysis set
|
169.9 Centimeter (cm)
STANDARD_DEVIATION 9.35 • n=358 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Weight: FAS72+ Analysis set
|
76.0 Kilogram (kg)
STANDARD_DEVIATION 19.15 • n=368 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants With Prior Hospitalizations Within 90 days Prior to Current Hospitalization
|
253 Participants
n=511 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants With Antibiotic Exposure Within 90 Days Prior to Index Hospitalization
|
260 Participants
n=511 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants With any Healthcare Procedure Within 30 Days Prior to Index Date
|
311 Participants
n=512 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Aminoglycosides
|
49 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Carbapenems
|
118 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Cephalosporins
|
73 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Fluoroquinolones
|
65 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Glycopeptides
|
81 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Glycylcycline
|
17 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Lipopeptides
|
17 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Macrolides
|
24 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Monobactam
|
5 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Nitroimidazole
|
26 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Other agents
|
65 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Oxazolidinones
|
27 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Penicillins
|
18 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Penicillins and beta-lactamase inhibitors
|
110 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Tetracycline
|
9 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Antibiotic Class Used Prior to Ceftazidime-Avibactam Initiation
Uncoded
|
48 Participants
n=259 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Country Travelled Within the Past 3 Months
Egypt
|
1 Participants
n=8 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for this baseline characteristic who travelled to other countries.
|
|
Number of Participants According to Country Travelled Within the Past 3 Months
Germany
|
1 Participants
n=8 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for this baseline characteristic who travelled to other countries.
|
|
Number of Participants According to Country Travelled Within the Past 3 Months
Italy
|
1 Participants
n=8 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for this baseline characteristic who travelled to other countries.
|
|
Number of Participants According to Country Travelled Within the Past 3 Months
Netherlands
|
1 Participants
n=8 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for this baseline characteristic who travelled to other countries.
|
|
Number of Participants According to Country Travelled Within the Past 3 Months
Pakistan
|
1 Participants
n=8 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for this baseline characteristic who travelled to other countries.
|
|
Number of Participants According to Country Travelled Within the Past 3 Months
Spain
|
2 Participants
n=8 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for this baseline characteristic who travelled to other countries.
|
|
Number of Participants According to Country Travelled Within the Past 3 Months
Turkey
|
1 Participants
n=8 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for this baseline characteristic who travelled to other countries.
|
|
Number of Participants With Reported Pregnancy
|
3 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Weeks of Gestation Since Last Menstrual Period
|
29.7 Weeks
STANDARD_DEVIATION 8.39 • n=3 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants With Alcohol use
|
41 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Alcoholic Drinks per Week: FAS72+ Analysis set
|
15.4 Drinks per week
STANDARD_DEVIATION 17.36 • n=31 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Tobacco use
Current Smoker
|
38 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Tobacco use
Previous Smoker
|
88 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Tobacco use
Never Smoked
|
165 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Tobacco use
Unknown
|
225 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Cigarettes per day
For current smokers
|
20.4 Cigarettes per day
STANDARD_DEVIATION 8.76 • n=32 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Cigarettes per day
For previous smokers
|
19.6 Cigarettes per day
STANDARD_DEVIATION 13.27 • n=58 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Source of Infection
Hospital-acquired infections (HAI)
|
354 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Source of Infection
Healthcare-associated infections (HCAI)
|
116 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Source of Infection
Community-acquired infection (CAI)
|
46 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants According to Other Indication for Ceftazidime-Avibactam
Surgical site infection (SSI)
|
15 Participants
n=209 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Other Indication for Ceftazidime-Avibactam
Central line associated blood stream infection (CLABSI)
|
15 Participants
n=209 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Other Indication for Ceftazidime-Avibactam
Bloodstream infection (BSI)/ Sepsis
|
97 Participants
n=209 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Other Indication for Ceftazidime-Avibactam
Meningitis
|
0 Participants
n=209 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Other Indication for Ceftazidime-Avibactam
Endocarditis
|
0 Participants
n=209 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Other Indication for Ceftazidime-Avibactam
Osteomyelitis
|
7 Participants
n=209 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Other Indication for Ceftazidime-Avibactam
Febrile neutropenia
|
24 Participants
n=209 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Other Indication for Ceftazidime-Avibactam
Other
|
51 Participants
n=209 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Bladder
|
2 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Kidney
|
2 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Large Intestine
|
5 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Lungs
|
29 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Liver
|
2 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Gall Bladder
|
2 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Pancreas
|
1 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Peritoneum
|
4 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Small Intestine
|
2 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Urethra
|
11 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Initial Site of Infection
Other
|
103 Participants
n=163 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants With Microbiological Cultures Performed for Current Infection Before Therapy
|
239 Participants
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Escherichia coli
|
21 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Klebsiella pneumoniae
|
140 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Klebsiella species (spp)
|
25 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Proteus mirabilis
|
6 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Proteus spp
|
1 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Acinetobacter baumannii
|
16 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Acinetobacter spp
|
1 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Enterobacter cloacae
|
17 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Enterobacter spp
|
5 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Citrobacter spp
|
1 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Serratia spp
|
3 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Morganella morganii
|
2 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Pseudomonas aeruginosa
|
30 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Pseudomonas spp
|
3 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Haemophilus spp
|
1 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-negative: Other
|
9 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-positive: Staphylococcus aureus
|
7 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-positive: Staphylococcus spp
|
5 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-positive: Enterococcus spp
|
23 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-positive: Streptococcus spp
|
5 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Gram-positive: Other
|
10 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Anaerobes: Bacteroides spp
|
1 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Pathogens Identified Before Ceftazidime-Avibactam Therapy
Other Bacterial Agent
|
3 Pathogens
n=239 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Acute Physiology and Chronic Health Evaluation (APACHE) II Score
|
19.5 Scores on a scale
STANDARD_DEVIATION 7.93 • n=46 Participants • Data is presented for FAS72+ analysis set. Here, 'Number Analyzed' signifies number of participants evaluable for the baseline characteristic.
|
|
Number of Participants According to Indication for Ceftazidime-Avibactam
FAS72+ · Complicated Urinary Tract Infection (cUTI)
|
103 Participants
n=516 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Indication for Ceftazidime-Avibactam
FAS72+ · Complicated Intra-Abdominal Infection (cIAI)
|
90 Participants
n=516 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Indication for Ceftazidime-Avibactam
FAS72+ · Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia (HAP/VAP)
|
114 Participants
n=516 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Indication for Ceftazidime-Avibactam
FAS72+ · Other
|
209 Participants
n=516 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Indication for Ceftazidime-Avibactam
FAS72- · Complicated Urinary Tract Infection (cUTI)
|
7 Participants
n=53 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Indication for Ceftazidime-Avibactam
FAS72- · Complicated Intra-Abdominal Infection (cIAI)
|
12 Participants
n=53 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Indication for Ceftazidime-Avibactam
FAS72- · Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia (HAP/VAP)
|
10 Participants
n=53 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants According to Indication for Ceftazidime-Avibactam
FAS72- · Other
|
24 Participants
n=53 Participants • Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
|
|
Number of Participants With Comorbidities
Any comorbidities
|
479 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
|
Number of Participants With Comorbidities
No comorbidities
|
37 Participants
n=516 Participants • Data is presented for FAS72+ analysis set.
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.
Number of participants who received at least one dose of ceftazidime-avibactam according to type of use as monotherapy or combination therapy was reported in this outcome measure. Index date was start date of ceftazidime-avibactam.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS 72+ Population
Combination therapy
|
358 Participants
|
|
Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS 72+ Population
Monotherapy
|
158 Participants
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72- population included all participants with \< 72 hours exposure to ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
Number of participants who received at least one dose of ceftazidime-avibactam according to type of use as monotherapy or combination therapy was reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=10 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS72- Population
Monotherapy
|
3 Participants
|
|
Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS72- Population
Combination therapy
|
7 Participants
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.
The total cumulative dose and daily dose of ceftazidime-avibactam was reported in this outcome measure. Total cumulative dose was defined as the sum of all doses received.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Total and Daily Dose of Ceftazidime-Avibactam: FAS72+ Population
Total dose
|
62.2 Milligram (mg)
Standard Deviation 55.82
|
|
Total and Daily Dose of Ceftazidime-Avibactam: FAS72+ Population
Daily dose
|
5.2 Milligram (mg)
Standard Deviation 1.52
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72- population included all participants with \< 72 hours exposure to ceftazidime-avibactam.
The total cumulative dose and daily dose of ceftazidime-avibactam was reported in this outcome measure. Total cumulative dose was defined as the sum of all doses received.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=53 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Total and Daily Dose of Ceftazidime-Avibactam: FAS72- Population
Total dose
|
6.3 Milligrams
Standard Deviation 3.65
|
|
Total and Daily Dose of Ceftazidime-Avibactam: FAS72- Population
Daily dose
|
4.8 Milligrams
Standard Deviation 1.96
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.
Number of participants classified according to frequency of dose (once daily \[OD\], every other day \[QOD\], post-dialysis, each 48 hours \[h\], three times daily \[TID\], twice daily \[BD\], four times daily \[QID\], once loading dose \[an initial higher dose of a drug that may be given at the beginning of a course of treatment before dropping down to a lower maintenance dose\], every three days, once, etc.,) for ceftazidime-avibactam were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
0.75 grams (g)*OD
|
4 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
0.75 g*QOD
|
4 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
0.75 g*Other: Post dialysis
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
0.75 g*Other: each 48 h
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
0.75 g*TID
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
0.75 g*BD
|
13 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
0.80 g*BD
|
2 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
0.94 g*BD
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.00 g*OD
|
6 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.00 g*QOD
|
2 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.00 g*QID
|
2 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.00 g*Other: Post dialysis
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.00 g*TID
|
51 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.00 g*BD
|
19 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.20 g*TID
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.25 g*TID
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
1.50 g*OD
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.00 g*OD
|
7 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.00 g*QOD
|
2 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.00 g*QID
|
5 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.00 g*Other: Once, loading dose
|
2 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.00 g*Other: every 3 days
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.00 g*Other: once
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.00 g*TID
|
400 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.00 g*BD
|
29 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72+ Population
2.50 g*OD
|
1 Participants
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72- population included all participants with \< 72 hours exposure to ceftazidime-avibactam.
Number of participants classified according to frequency of dose (once daily \[OD\], every other day \[QOD\], each 48 hours \[h\], continuous infusion per 48 hours \[c/48 h\], three times daily \[TID\], twice daily \[BD\], four times daily \[QID\], one dose, loading dose \[an initial higher dose of a drug that may be given at the beginning of a course of treatment before dropping down to a lower maintenance dose\] etc.,) for ceftazidime-avibactam were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=53 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
0.75 g*Other: 48 h
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
0.94 g*QOD
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
1.00 g*OD
|
2 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
1.00 g*QOD
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
1.00 g*Other: 48 h
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
1.00 g*Other: c/48h
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
1.00 g*TID
|
3 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
1.87 g*BD
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
2.00 g*OD
|
3 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
2.00 g*QID
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
2.00 g*Other: Loading dose
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
2.00 g*Other: one dose
|
1 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
2.00 g*TID
|
34 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
2.00 g*BD
|
4 Participants
|
|
Number of Participants Classified According to Frequency of Dosing: FAS72- Population
3.00 g*BD
|
1 Participants
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.
Total duration of administration was calculated as stop date of administration of ceftazidime-avibactam minus start date of ceftazidime-avibactam administration plus 1.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Total Duration of Administration of Ceftazidime-Avibactam: FAS72+ Population
|
9.0 Days
Interval 2.0 to 179.0
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72- population included all participants with \< 72 hours exposure to ceftazidime-avibactam.
Total duration of administration was calculated as stop date of administration of ceftazidime-avibactam minus start date of ceftazidime-avibactam administration plus 1.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=53 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Total Duration of Administration of Ceftazidime-Avibactam: FAS72- Population
|
1.0 Days
Interval 1.0 to 3.0
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
Number of participants according to the reasons for discontinuation of ceftazidime-avibactam were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=506 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Adverse events (AEs)
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Perceived clinical failure/disease progression
|
10 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Isolation of a resistant pathogen
|
9 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Preference for empiric coverage
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Secondary infection requiring regimen change
|
11 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Switch to oral therapy
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
De-escalation
|
59 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Cure
|
329 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Death
|
50 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population
Other
|
28 Participants
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72- population included all participants with \< 72 hours exposure to ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
Number of participants according to the reasons for discontinuation of ceftazidime-avibactam were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=52 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Adverse events (AEs)
|
0 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Isolation of a resistant pathogen
|
6 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Preference for empiric coverage
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Secondary infection requiring regimen change
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Switch to oral therapy
|
0 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
De-escalation
|
23 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Death
|
14 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population
Other
|
4 Participants
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.
The number of participants classified according to antibiotics used concurrently with ceftazidime-avibactam were reported in this outcome measure. Participants could have received more than 1 antibiotic.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Fluoroquinolones: Ofloxacin ear drops
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Aminoglycoside: Amikacin
|
58 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Aminoglycoside: Gentamicin
|
19 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Aminoglycoside: Tobramycin
|
6 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Amphenicol: Chloramphenicol
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Carbapenems: Doripenem
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Carbapenems: Ertapenem
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Carbapenems: Imipenem
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Carbapenems: Meropenem
|
28 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Cephalosporins: Ceftazidime
|
4 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Glycopeptides: Teicoplanin
|
18 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Glycopeptides: Telavancin
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Glycopeptides: Vancomycin
|
65 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Glycylcycline: Tigecycline
|
49 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Lipopeptides: Daptomycin
|
21 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Macrolides: Azithromycin
|
4 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Macrolides: Clarithromycin
|
2 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Macrolides: Clindamycin
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Macrolides: Erythromycin
|
6 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Macrolides: Fidaxomicin
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Monobactam: Aztreonam
|
104 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Nitroimidazole: Metronidazole
|
60 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Oxazolidinones: Linezolid
|
37 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Oxazolidinones: Tedizolid
|
4 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Penicillins: Amoxicillin
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Penicillins: Ampicillin
|
8 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Penicillins: Benzylpenicillin
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Penicillins: Flucloxacillin
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Penicillins: Ticarcillin
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Penicillins and beta-lactamase inhibitors: Amoxicillin-clavulanate
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Penicillins and beta-lactamase inhibitors: Ampicillin-sulbactam
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Penicillins and beta-lactamase inhibitors: Piperacillin-tazobactam
|
5 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Fluoroquinolones: Ciprofloxacin
|
15 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Fluoroquinolones: Levofloxacin
|
5 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Fluoroquinolones: Moxifloxacin
|
3 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Tetracycline: Doxycycline
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Other agents
|
123 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Polymyxins: Colistin
|
60 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Polymyxins: Polymyxin B
|
15 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole
|
21 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Other antibiotics: Clofazimine
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Other antibiotics: Ethambutol
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Other antibiotics: Fosfomycin
|
12 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Other antibiotics: Isoniazid
|
2 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Other antibiotics: Rifampicin
|
1 Participants
|
|
Number of Participants Classified According to Antibiotics Used Concurrently: FAS 72+ Population
Other antibiotics: Rifaximin
|
1 Participants
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
The number of participants classified according to reason for initiating specific antibiotics combined with ceftazidime-avibactam were reported in this outcome measure. One participant could have received more than 1 antibiotics and there could be more than 1 reason for initiating antibiotics.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Amikacin: Empiric treatment
|
7 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Amikacin: Failure of antimicrobial treatment
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Amikacin: Infection
|
30 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Amikacin: Microbiology
|
18 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Amikacin: Prophylaxis
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Amikacin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Amoxicillin: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Amoxicillin-clavulanate: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ampicillin: Infection
|
3 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ampicillin: Microbiology
|
4 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ampicillin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ampicillin-sulbactam: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Aztreonam: Disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Aztreonam: Empiric treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Aztreonam: Failure of antimicrobial treatment
|
4 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Aztreonam: Infection
|
23 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Aztreonam: Microbiology
|
73 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Aztreonam: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ceftazidime: Infection
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ceftazidime: Microbiology
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Chloramphenicol: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ciprofloxacin: Infection
|
8 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ciprofloxacin: Microbiology
|
6 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ciprofloxacin: Prophylaxis
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Doripenem: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ertapenem: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Gentamicin: Empiric treatment
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Gentamicin: Infection
|
5 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Gentamicin: Microbiology
|
13 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Imipenem: Empiric treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Levofloxacin: Infection
|
3 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Levofloxacin: Microbiology
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Meropenem: Empiric treatment
|
3 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Meropenem: Infection
|
14 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Meropenem: Microbiology
|
9 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Meropenem: Prophylaxis
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Meropenem: Other
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Moxifloxacin: Infection
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Moxifloxacin: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Piperacillin-tazobactam: Empiric treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Piperacillin-tazobactam: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Piperacillin-tazobactam: Microbiology
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ticarcillin: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tigecycline: Disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tigecycline: Empiric treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tigecycline: Failure of antimicrobial treatment
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tigecycline: Infection
|
21 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tigecycline: Microbiology
|
20 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tigecycline: Other
|
3 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tobramycin: Infection
|
5 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tobramycin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Empiric treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Infection
|
30 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Microbiology
|
27 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Other
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Polymyxins: Polymyxin B: Infection
|
6 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Polymyxins: Polymyxin B: Microbiology
|
9 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Empiric treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Failure of antimicrobial treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Infection
|
5 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Microbiology
|
8 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Prophylaxis
|
5 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Other antibiotics: Fosfomycin: Disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Other antibiotics: Fosfomycin: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Other antibiotics: Fosfomycin: Microbiology
|
8 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Other antibiotics: Fosfomycin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Other antibiotics: Rifampicin: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Azithromycin: Infection
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Azithromycin: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Azithromycin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Benzylpenicillin: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Clarithromycin: Microbiology
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Clindamycin: Empiric treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Daptomycin: Empiric treatment
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Daptomycin: Infection
|
16 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Daptomycin: Microbiology
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Daptomycin: Other
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Doxycycline: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Erythromycin: Infection
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Erythromycin: Other
|
4 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Fidaxomicin: Clostridium difficile
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Flucloxacillin: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Linezolid: Disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Linezolid: Empiric treatment
|
6 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Linezolid: Failure of antimicrobial treatment
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Linezolid: Infection
|
15 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Linezolid: Microbiology
|
13 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tedizolid: Infection
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Tedizolid: Microbiology
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Teicoplanin: Clostridium difficile
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Teicoplanin: Disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Teicoplanin: Empiric treatment
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Teicoplanin: Infection
|
4 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Teicoplanin: Microbiology
|
7 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Teicoplanin: Prophylaxis
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Telavancin: Disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Vancomycin: Clostridium difficile
|
6 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Vancomycin: Empiric treatment
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Vancomycin: Infection
|
40 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Vancomycin: Microbiology
|
14 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Vancomycin: Prophylaxis
|
3 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Vancomycin: Other
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Other antibiotics: Rifaximin: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Metronidazole: Clostridium difficile
|
9 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Metronidazole: Empiric treatment
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Metronidazole: Failure of antimicrobial treatment
|
2 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Metronidazole: Infection
|
28 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Metronidazole: Microbiology
|
18 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Metronidazole: Prophylaxis
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Metronidazole: Other
|
3 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ofloxacin ear drops: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Other antibiotics: Clofazimine: Infection
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Ethambutol: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Isoniazid: Microbiology
|
1 Participants
|
|
Number of Participants Classified According to Reason for Initiating Antibiotics: FAS 72+ Population
Isoniazid: Prophylaxis
|
1 Participants
|
PRIMARY outcome
Timeframe: From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, "Number Analyzed" signifies number of participants evaluable for the specified rows.
The number of participants classified according to reason for discontinuing specific antibiotics combined with ceftazidime-avibactam were reported in this outcome measure. One participant could have received more than 1 antibiotics and there could be more than 1 reason for discontinuing antibiotics.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amikacin: Perceived clinical failure/disease progression
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amikacin: Isolation of a resistant pathogen
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amikacin: Preference for empiric coverage
|
6 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amikacin: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amikacin: De-escalation
|
13 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amikacin: Cure
|
15 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amikacin: Death
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amikacin: Other
|
15 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amoxicillin: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Amoxicillin-clavulanate: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ampicillin: Switch to oral therapy
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ampicillin: Cure
|
6 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ampicillin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ampicillin-sulbactam: De-escalation
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: Perceived clinical failure/disease progression
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: Isolation of a resistant pathogen
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: Preference for empiric coverage
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: Switch to oral therapy
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: De-escalation
|
11 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: Cure
|
66 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: Death
|
11 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Aztreonam: Other
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ceftazidime: De-escalation
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ceftazidime: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ceftazidime: Death
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ceftazidime: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Chloramphenicol: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ciprofloxacin: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ciprofloxacin: Isolation of a resistant pathogen
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ciprofloxacin: Preference for empiric coverage
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ciprofloxacin: Switch to oral therapy
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ciprofloxacin: De-escalation
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ciprofloxacin: Cure
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ciprofloxacin: Death
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ciprofloxacin: Other
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Doripenem: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ertapenem: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Gentamicin: Isolation of a resistant pathogen
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Gentamicin: Preference for empiric coverage
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Gentamicin: De-escalation
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Gentamicin: Cure
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Gentamicin: Other
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Imipenem: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Levofloxacin: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Levofloxacin: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Levofloxacin: De-escalation
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Levofloxacin: Death
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Levofloxacin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: AE
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: Perceived clinical failure/disease progression
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: Isolation of a resistant pathogen
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: Preference for empiric coverage
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: Switch to oral therapy
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: De-escalation
|
6 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: Cure
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: Death
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Meropenem: Other
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Moxifloxacin: Switch to oral therapy
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Moxifloxacin: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Moxifloxacin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Piperacillin-tazobactam: Preference for empiric coverage
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Piperacillin-tazobactam: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Piperacillin-tazobactam: De-escalation
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Piperacillin-tazobactam: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ticarcillin: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tigecycline: AE
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tigecycline: Perceived clinical failure/disease progression
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tigecycline: Isolation of a resistant pathogen
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tigecycline: De-escalation
|
8 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tigecycline: Cure
|
23 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tigecycline: Death
|
9 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tigecycline: Other
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tobramycin: Preference for empiric coverage
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tobramycin: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tobramycin: Cure
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tobramycin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Colistin: AE
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Perceived clinical failure/disease progression
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Isolation of a resistant pathogen
|
6 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Preference for empiric coverage
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Colistin: De-escalation
|
15 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Cure
|
19 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Death
|
11 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Colistin: Other
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Polymyxin B: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Polymyxin B: Isolation of a resistant pathogen
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Polymyxin B: De-escalation
|
6 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Polymyxin B: Cure
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Polymyxin B: Death
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Polymyxins: Polymyxin B: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole (sulfa) : AE
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfa: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Preference for empiric coverage
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfa: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: De-escalation
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Cure
|
7 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Death
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Sulfonamides and Trimethoprim: Trimethoprim-sulfamethoxazole: Other
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Fosfomycin: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Fosfomycin: Isolation of a resistant pathogen
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Fosfomycin: De-escalation
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Fosfomycin: Cure
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Fosfomycin: Death
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Rifampicin: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Azithromycin: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Azithromycin: Preference for empiric coverage
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Azithromycin: Other
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Benzylpenicillin: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Clarithromycin: De-escalation
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Clarithromycin: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Clindamycin: Preference for empiric coverage
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Daptomycin: AE
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Daptomycin: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Daptomycin: Isolation of a resistant pathogen
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Daptomycin: Switch to oral therapy
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Daptomycin: De-escalation
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Daptomycin: Cure
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Daptomycin: Death
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Daptomycin: Other
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Doxycycline: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Erythromycin: De-escalation
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Erythromycin: Cure
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Erythromycin: Death
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Erythromycin: Other
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Fidaxomicin: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Flucloxacillin: Preference for empiric coverage
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: AE
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: Isolation of a resistant pathogen
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: Preference for empiric coverage
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: Secondary infection requiring regimen change
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: Switch to oral therapy
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: De-escalation
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: Cure
|
18 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Linezolid: Death
|
8 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tedizolid: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Tedizolid: Cure
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Teicoplanin: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Teicoplanin: De-escalation
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Teicoplanin: Cure
|
7 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Teicoplanin: Death
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Teicoplanin: Other
|
6 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Telavancin: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: AE
|
3 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: Isolation of a resistant pathogen
|
5 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: Preference for empiric coverage
|
6 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: Secondary infection requiring regimen change
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: Switch to oral therapy
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: De-escalation
|
10 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: Cure
|
30 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: Death
|
2 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Vancomycin: Other
|
8 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Rifaximin: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Metronidazole: Perceived clinical failure/disease progression
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Metronidazole: Preference for empiric coverage
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Metronidazole: De-escalation
|
8 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Metronidazole: Cure
|
32 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Metronidazole: Death
|
7 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Metronidazole: Other
|
11 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ofloxacin ear drops: Cure
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Clofazimine: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Ethambutol: Other
|
1 Participants
|
|
Number of Participants Classified According to Reason for Discontinuing Antibiotics: FAS 72+ Population
Isoniazid: Other
|
2 Participants
|
PRIMARY outcome
Timeframe: From end of index therapy up to 60 days after hospital discharge, in-hospital death, withdrawal from study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)Population: MOD population included all participants with at least 72 hours exposure to ceftazidime-avibactam, identification of one or more pathogens before the start of ceftazidime-avibactam treatment, and at least one non-missing microbiological outcome. Not all participants of MOD population had data collected after end of ceftazidime-avibactam therapy. Hence, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of participants whose samples were taken for clinical microbiological evaluation after end of ceftazidime-avibactam therapy were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=20 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Whose Samples Were Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: Microbiology Outcomes Dataset (MOD) Population
|
20 Participants
|
PRIMARY outcome
Timeframe: From end of index therapy up to 60 days after hospital discharge, in-hospital death, withdrawal from study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)Population: MOD population included all participants with at least 72 hours exposure to ceftazidime-avibactam, identification of one or more pathogens before the start of ceftazidime-avibactam treatment, and at least one non-missing microbiological outcome. Not all participants of MOD population had data collected after end of ceftazidime-avibactam therapy. Hence, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of participants classified according to the type of specimen taken for clinical microbiological evaluation after end of ceftazidime-avibactam therapy were reported in this outcome measure. More than 1 type of specimen could have been taken from 1 participant.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=20 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Blood
|
10 Participants
|
|
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Urine
|
4 Participants
|
|
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Bronchoalveolar lavage
|
4 Participants
|
|
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Sputum
|
5 Participants
|
|
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Abscess drainage
|
1 Participants
|
|
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Swab
|
3 Participants
|
|
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Surgical/biopsy specimen
|
1 Participants
|
|
Number of Participants Classified According to Type of Specimen Taken for Clinical Microbiological Evaluation After End of Ceftazidime-Avibactam Therapy: MOD Population
Other
|
5 Participants
|
PRIMARY outcome
Timeframe: After treatment initiation up to 60 days post hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)Population: MOD population included all participants with at least 72 hours exposure to ceftazidime-avibactam, identification of one or more pathogens before the start of ceftazidime-avibactam treatment, and at least one non-missing microbiological outcome. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of participants classified according to the pathogens identified from the microbiological culture after treatment initiation were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=69 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Escherichia coli
|
4 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Klebsiella pneumoniae
|
15 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Proteus mirabilis
|
1 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Acinetobacter baumannii
|
6 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Enterobacter cloacae
|
2 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Enterobacter species (spp)
|
1 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Serratia spp
|
2 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Morganella morganii
|
1 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Pseudomonas aeruginosa
|
8 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Pseudomonas spp
|
2 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-negative: Other
|
8 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-positive: Staphylococcus spp
|
6 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-positive: Enterococcus spp
|
14 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Gram-positive: Other
|
3 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Anaerobes: Clostridium spp
|
1 Participants
|
|
Number of Participants Classified According to the Pathogens Identified From the Microbiological Culture After Treatment Initiation: MOD Population
Other Bacterial Agent
|
1 Participants
|
PRIMARY outcome
Timeframe: After treatment initiation up to 60 days post hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of gram-negative pathogens according to the susceptibility to specific antibiotics after treatment initiation were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=52 Pathogens
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors
|
30 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Aminoglycosides
|
39 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Amphenicol
|
2 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Carbapenems
|
39 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Carbapenems: Doripenem
|
13 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Carbapenems: Ertapenem
|
17 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Carbapenems: Imipenem
|
31 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Carbapenems: Meropenem
|
36 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins
|
35 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefalexin
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefazolin
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefepime
|
12 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefixime
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefotaxime
|
13 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefoxitin
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefpodoxime
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Ceftaroline
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Ceftazidime
|
27 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Ceftriaxone
|
7 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefuroxime
|
2 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor
|
6 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor: Ceftazidime/avibactam
|
5 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor: Cefoperazone/sulbactam
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor: Ceftolozane/tazobactam
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Glycopeptides
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Glycylcycline
|
4 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Lipopeptides
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Macrolides
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Monobactam
|
9 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Nitroimidazole
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Oxazolidinones
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Penicillins
|
2 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors: Ampicillin-sulbactam
|
3 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors: Amoxicillin-clavulanate
|
15 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors: Piperacillin-tazobactam
|
14 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors: Ticarcillin-clavulanate
|
3 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Fluoroquinolones
|
40 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Streptogramins
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Tetracycline
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Other Agents
|
13 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Other Agents: Colistin
|
7 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Other Agents: Trimethoprim
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Other Agents: Trimethoprim-sulfamethoxazole
|
6 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Other Agents: Fosfomycin
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Susceptibility to Antibiotics After Treatment Initiation: FAS72+ Population
Other Agents: Nitrofurantoin
|
0 Pathogens
|
PRIMARY outcome
Timeframe: After treatment initiation up to 60 days post hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
Multi-drug resistance was defined as the isolate being non-susceptible to at least one agent in more than or equal to (\>=) 3 antimicrobial categories, excluding the therapeutic classes to which the pathogen was intrinsically resistant. The number of gram-negative pathogens classified according to the antibiotic resistance to specified antibiotics after treatment initiation were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=26 Pathogens
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Aminoglycosides
|
21 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Amphenicol
|
2 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Carbapenems
|
25 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Carbapenems: Doripenem
|
13 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Carbapenems: Ertapenem
|
12 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Carbapenems: Imipenem
|
20 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Carbapenems: Meropenem
|
25 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins
|
24 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefalexin
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefazolin
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefepime
|
6 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefixime
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefotaxime
|
9 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefoxitin
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefpodoxime
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Ceftaroline
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Ceftazidime
|
24 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Ceftriaxone
|
6 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporins: Cefuroxime
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor
|
4 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor: Ceftazidime/avibactam
|
4 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor: Cefoperazone/sulbactam
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor: Ceftolozane/tazobactam
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Cephalosporin/beta-lactamase inhibitor: Glycopeptides
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Glycylcycline
|
2 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Lipopeptides
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Macrolides
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Monobactam
|
9 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Nitroimidazole
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Oxazolidinones
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Penicillins
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors
|
21 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors: Ampicillin-sulbactam
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors: Amoxicillin-clavulanate
|
12 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors: Piperacillin-tazobactam
|
8 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Penicillins and beta-lactamase inhibitors: Ticarcillin-clavulanate
|
3 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Fluoroquinolones
|
24 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Streptogramins
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Tetracycline
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Other Agents
|
5 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Other Agents: Colistin
|
4 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Other Agents: Trimethoprim
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Other Agents: Trimethoprim-sulfamethoxazole
|
1 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Other Agents: Fosfomycin
|
0 Pathogens
|
|
Number of Gram-Negative Pathogens According to the Multi-Drug Resistance After Treatment Initiation: FAS72+ Population
Other Agents: Nitrofurantoin
|
0 Pathogens
|
PRIMARY outcome
Timeframe: At initial hospitalization (from the data evaluated in approximately 40 months of this study)Population: COD population included all participants with at least 72 hours exposure to ceftazidime-avibactam and at least one non-missing clinical outcome.
The number of participants classified according to type of clinical evaluation outcome as success, failure or indeterminate. Success: resolution of all signs and symptoms of infection with no need for escalation of antimicrobials for gram-negative coverage. Failure: inadequate response to ceftazidime-avibactam therapy or resistant, worsening, or new recurrent signs and symptoms at the end of ceftazidime-avibactam therapy. Indeterminate: there was not enough information to conclude whether the antibiotic regimen containing ceftazidime-avibactam was a clinical failure or a success.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome at Initial Hospitalization: Clinical Outcomes Dataset (COD) Population
Success
|
399 Participants
|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome at Initial Hospitalization: Clinical Outcomes Dataset (COD) Population
Failure
|
60 Participants
|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome at Initial Hospitalization: Clinical Outcomes Dataset (COD) Population
Indeterminate
|
57 Participants
|
PRIMARY outcome
Timeframe: 60 days after hospital discharge (from the data evaluated in approximately 40 months of this study)Population: COD population included all participants with at least 72 hours exposure to ceftazidime-avibactam and at least one non-missing clinical outcome. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of participants classified according to type of clinical evaluation outcome as success, failure or indeterminate. Success: resolution of all signs and symptoms of infection with no need for escalation of antimicrobials for gram-negative coverage. Failure: inadequate response to ceftazidime-avibactam therapy or resistant, worsening, or new recurrent signs and symptoms at the end of ceftazidime-avibactam therapy. Indeterminate: there was not enough information to conclude whether the antibiotic regimen containing ceftazidime-avibactam was a clinical failure or a success.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=317 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome 60 Days Post-Discharge: Clinical Outcomes Dataset (COD) Population
Success
|
266 Participants
|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome 60 Days Post-Discharge: Clinical Outcomes Dataset (COD) Population
Failure
|
27 Participants
|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome 60 Days Post-Discharge: Clinical Outcomes Dataset (COD) Population
Indeterminate
|
24 Participants
|
PRIMARY outcome
Timeframe: 60 days post treatment (from the data evaluated in approximately 40 months of this study)Population: COD population included all participants with at least 72 hours exposure to ceftazidime-avibactam and at least one non-missing clinical outcome. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of participants classified according to type of clinical evaluation outcome as success, failure or indeterminate. Success: resolution of all signs and symptoms of infection with no need for escalation of antimicrobials for gram-negative coverage. Failure: inadequate response to ceftazidime-avibactam therapy or resistant, worsening, or new recurrent signs and symptoms at the end of ceftazidime-avibactam therapy. Indeterminate: there was not enough information to conclude whether the antibiotic regimen containing ceftazidime-avibactam was a clinical failure or a success.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=374 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome 60 Days Post-Treatment: Clinical Outcomes Dataset (COD) Population
Success
|
311 Participants
|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome 60 Days Post-Treatment: Clinical Outcomes Dataset (COD) Population
Failure
|
32 Participants
|
|
Number of Participants Classified According to Type of Clinical Evaluation Outcome 60 Days Post-Treatment: Clinical Outcomes Dataset (COD) Population
Indeterminate
|
31 Participants
|
PRIMARY outcome
Timeframe: Up to 14 days post first dose of ceftazidime-avibactam (from the data evaluated in approximately 40 months of the study)Population: Planned analysis of this outcome measure was cancelled on approval of Scientific Steering Committee as few participants had microbiological cultures after the start of ceftazidime-avibactam.
The number of participants with microbiological treatment outcome as success were reported in this outcome measure. Success was defined as: absence of causative pathogen from appropriately obtained specimens at the site of infection.
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Up to 90 days prior to index date (from the data evaluated in approximately 40 months of this study)Population: FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.
The number of participants classified according to antibiotics used (Yes or No) for current infection before ceftazidime-avibactam were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Antibiotics Used for Current Infection Before Ceftazidime-Avibactam: FAS72+ Population
Yes
|
397 Participants
|
|
Number of Participants Classified According to Antibiotics Used for Current Infection Before Ceftazidime-Avibactam: FAS72+ Population
No
|
119 Participants
|
PRIMARY outcome
Timeframe: Up to 90 days prior to index date (from the data evaluated in approximately 40 months of this study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of participants classified according to reason for discontinuing for prior antibiotic therapy were reported in this outcome measure. One participant could have more than 1 reason of discontinuation for prior antibiotic therapy.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=389 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
AE
|
11 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Perceived clinical failure/disease progression
|
134 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Isolation of a resistant pathogen
|
236 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Preference for empiric coverage
|
32 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Secondary infection requiring regimen change
|
35 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Switch to oral therapy
|
4 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
De-escalation
|
58 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Cure
|
53 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Death
|
11 Participants
|
|
Number of Participants Classified According to Reason for Discontinuation for Prior Antibiotic Therapy: FAS72+ Population
Other
|
69 Participants
|
PRIMARY outcome
Timeframe: During index hospitalization, maximum of 418 days (from the data evaluated in approximately 40 months of this study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.
In hospital-mortality was defined as deaths occurring after treatment initiation but before hospital discharge. The percentage of participants who died during index hospitalization were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Percentage of Participants Who Died During Index Hospitalization
|
23.1 Percentage of participants
Interval 19.5 to 26.9
|
PRIMARY outcome
Timeframe: From index treatment up to 30 days post hospital discharge, maximum of 434 days (from the data evaluated in approximately 40 months of this study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.
30-day mortality was defined as deaths occurred from index treatment up to within 30 days after hospital discharge including in-hospital mortality.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Percentage of Participants Who Died Within the 30 Days After Hospital Discharge (Including In-Hospital Mortality): FAS72+ Population
|
24.6 Percentage of participants
Interval 21.0 to 28.6
|
PRIMARY outcome
Timeframe: From index treatment up to 60 days post hospital discharge, maximum of 434 days (from the data evaluated in approximately 40 months of this study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.
60-day mortality was defined as deaths occurred from index treatment up to within 60 days after hospital discharge including in-hospital mortality.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Percentage of Participants Who Died Within 60 Days After Hospital Discharge (Including In-Hospital Mortality): FAS72+ Population
|
27.9 Percentage of participants
Interval 24.1 to 32.0
|
PRIMARY outcome
Timeframe: From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 464 days (from the data evaluated in approximately 40 months of the study)Population: FAS population included all enrolled participants meeting the study eligibility criteria.
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. AE included both SAEs and non-SAEs. SAE was defined as any untoward medical occurrence at any dose that: resulted in death, was life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required hospitalization or prolongation of existing hospitalization. Only AEs and SAEs with explicit attribution to ceftazidime-avibactam that appeared in the reviewed information and scenarios involving drug exposure to ceftazidime-avibactam, which included exposure during pregnancy, exposure during breastfeeding, medication error, overdose, misuse, extravasation, lack of efficacy and occupational exposure associated with the use of ceftazidime-avibactam were collected in the study.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=569 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Any adverse event
|
6 Participants
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Any serious adverse event
|
5 Participants
|
PRIMARY outcome
Timeframe: From index date up to hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first maximum of 418 days (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
Hospital length of stay (LOS) was defined as date of hospital discharge minus date of hospital admission plus 1. The duration of hospital stay of participants were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=514 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Duration of Hospital Stay: FAS72+ Population
|
36.0 Days
Interval 3.0 to 418.0
|
PRIMARY outcome
Timeframe: During index hospitalization, maximum up to 418 days (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
Duration of ICU stay was defined as date of ICU discharge minus date of ICU admission plus 1. The total duration of ICU stay of participants were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=275 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Total Duration of ICU Stay: FAS72+ Population
|
24.0 Days
Interval 1.0 to 405.0
|
PRIMARY outcome
Timeframe: Up to 30 days after initial discharge (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.
The number of participants readmitted to the hospital during the 30 days after initial discharge were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Readmitted to the Hospital During the 30 Days After Initial Discharge: FAS72+ Population
|
111 Participants
|
PRIMARY outcome
Timeframe: Up to 60 days after initial discharge (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.
The number of participants readmitted to the hospital during the 60 days after initial discharge were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Readmitted to the Hospital During the 60 Days After Initial Discharge: FAS72+ Population
|
53 Participants
|
PRIMARY outcome
Timeframe: At readmission to the hospital, up to maximum of 60 days post initial hospital discharge (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of participants classified according to the reason for readmission to the hospital were reported in this outcome measure. One participant could have more than 1 reason for readmission to the hospital.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=137 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to Reason for Readmission to the Hospital: FAS72+ Population
Secondary infection
|
17 Participants
|
|
Number of Participants Classified According to Reason for Readmission to the Hospital: FAS72+ Population
Unrelated to the infection
|
98 Participants
|
|
Number of Participants Classified According to Reason for Readmission to the Hospital: FAS72+ Population
Infection recurrence
|
25 Participants
|
|
Number of Participants Classified According to Reason for Readmission to the Hospital: FAS72+ Population
Unknown
|
6 Participants
|
PRIMARY outcome
Timeframe: During index hospitalization maximum of 418 days (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.
The number of participants classified according to the healthcare resource utilization during the hospitalization were reported in this outcome measure. One participant could have utilized more than 1 healthcare resource during hospitalization.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=516 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to the Healthcare Resource Utilized During the Hospitalization: FAS72+ Population
Surgical intervention
|
169 Participants
|
|
Number of Participants Classified According to the Healthcare Resource Utilized During the Hospitalization: FAS72+ Population
Percutaneous procedures
|
149 Participants
|
|
Number of Participants Classified According to the Healthcare Resource Utilized During the Hospitalization: FAS72+ Population
Other
|
73 Participants
|
|
Number of Participants Classified According to the Healthcare Resource Utilized During the Hospitalization: FAS72+ Population
Mechanical ventilation
|
161 Participants
|
|
Number of Participants Classified According to the Healthcare Resource Utilized During the Hospitalization: FAS72+ Population
Hemodialysis
|
80 Participants
|
|
Number of Participants Classified According to the Healthcare Resource Utilized During the Hospitalization: FAS72+ Population
CT/MRI imaging
|
273 Participants
|
|
Number of Participants Classified According to the Healthcare Resource Utilized During the Hospitalization: FAS72+ Population
Tracheostomy
|
83 Participants
|
PRIMARY outcome
Timeframe: During index hospitalization maximum of 418 days (from the data evaluated in approximately 40 months of the study)Population: FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.
The number of participants classified according to all wards attended during hospitalization were reported in this outcome measure.
Outcome measures
| Measure |
Ceftazidime-avibactam
n=515 Participants
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Number of Participants Classified According to All Wards Attended During Hospitalization: FAS72+ Population
Surgical
|
101 Participants
|
|
Number of Participants Classified According to All Wards Attended During Hospitalization: FAS72+ Population
Medical
|
195 Participants
|
|
Number of Participants Classified According to All Wards Attended During Hospitalization: FAS72+ Population
Onco-hematology
|
58 Participants
|
|
Number of Participants Classified According to All Wards Attended During Hospitalization: FAS72+ Population
Infectious disease
|
27 Participants
|
|
Number of Participants Classified According to All Wards Attended During Hospitalization: FAS72+ Population
ICU
|
116 Participants
|
|
Number of Participants Classified According to All Wards Attended During Hospitalization: FAS72+ Population
Other
|
18 Participants
|
Adverse Events
Ceftazidime-avibactam
Serious events: 5 serious events
Other events: 2 other events
Deaths: 170 deaths
Serious adverse events
| Measure |
Ceftazidime-avibactam
n=569 participants at risk
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
General disorders
Multiple organ dysfunction syndrome
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Hepatobiliary disorders
Cholestasis
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Hepatobiliary disorders
Hepatocellular injury
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Nervous system disorders
Altered state of consciousness
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Nervous system disorders
Neurotoxicity
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Skin and subcutaneous tissue disorders
Stevens-Johnson syndrome
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
Other adverse events
| Measure |
Ceftazidime-avibactam
n=569 participants at risk
Eligible participants who were hospitalized with gram negative infections and received at least one dose of ceftazidime-avibactam in routine clinical practice since 01-Jan-2018 were included in this chart review study.
|
|---|---|
|
Gastrointestinal disorders
Diarrhoea
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Eye disorders
Blurred vision
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Psychiatric disorders
Confusional state
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
|
Psychiatric disorders
Disorientation
|
0.18%
1/569 • From index date up to 60 days after hospital discharge, in-hospital death, withdrawal from the study, or lost to follow-up, whichever occurred first (up to maximum of 464 days)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Only SAEs and non-SAEs with an explicit attribution to or associated with use of ceftazidime-avibactam from the data captured in medical records were collected in this study.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER